AUTHORS
Jackie A Fretz, PhD, Jodie L Babitt, MD2, Karin Elisabeth Finberg, MD, PhD3
AFFILIATIONS
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
ABSTRACT
Iron deficiency anemia (IDA) is a potent stimulator of FGF23 (fibroblast growth factor 23), a phosphaturic hormone produced by bone-embedded osteocytes. Previously, we identified bone marrow (BM) sinusoidal endothelial cells (SEC) as a novel site of Fgf23 upregulation in IDA using the Tmprss6-/- (knockout) model of Iron-Refractory Iron Deficiency Anemia (IRIDA), and we identified erythropoietin (EPO) as an inducer of Fgf23 expression in BM-SEC. Here, we used the Stab2-iCreF3 allele (conferring Cre recombinase activity in SEC of liver, spleen, lymph node, and BM, but not hematopoietic cells or their progeny) with an Fgf23 conditional knockout allele to generate mice with Fgf23 disruption in SEC (Fgf23SEC/SEC) and to disrupt Fgf23 in SEC of Tmprss6-/- mice. To investigate physiological consequences of Fgf23 disruption in SEC in normal mice and in IDA, we assessed male mice at both young (8-9 weeks; n=6-11/group) and older (40-47 weeks; n=4-8/group) ages and compared physical and hematological parameters by 2-tailed unpaired t-test (means values shown, P<0.05 considered significant).
Fgf23fl/fl and Fgf23SEC/SEC males showed normal complete blood counts and spleen weights at both young and older ages. Interestingly, older Fgf23SEC/SEC mice had significantly lower body mass than older Fgf23fl/fl mice; this difference was not attributable to the Stab2-iCreF3 allele alone because body mass in older Fgf23SEC/+ and Fgf23fl/fl mice was similar. Consistent with the known role of Tmprss6 as a negative regulator of hepcidin expression, young Tmprss6-/-Fgf23fl/fl mice showed microcytic anemia, thrombocytosis, increased spleen/body mass ratio, and decreased body mass when compared with young Fgf23fl/fl mice. Tmprss6-/-Fgf23fl/fl mice also showed elevated levels of serum EPO and plasma C-terminal FGF23 (c-FGF23; a measure of both intact hormone and C-terminal cleaved fragments) when compared with non-anemic mice. However, this plasma cFGF23 elevation was not significantly altered by Fgf23 disruption in SEC of young Tmprss6-/- male mice (Tmprss6-/-Fgf23SEC/SEC). Additionally, young Tmprss6-/-Fgf23fl/fl and Tmprss6-/-Fgf23SEC/SEC mice showed similar degrees of anemia, thrombocytosis, splenomegaly, and EPO elevation, with similarly reduced body mass.
When compared with younger Tmprss6-/-Fgf23fl/fl males, older Tmprss6-/-Fgf23fl/fl mice showed significantly lower red blood cell count (RBC,10.02 vs 11.51 M/mL), greater spleen mass (0.2209 vs 0.0754 g), higher serum EPO (4107 vs 1152 pg/mL), higher plasma c-FGF23 (2211 vs 770 pg/mL) and greater body mass (28 vs 19 g). Intriguingly, in older Tmprss6-/- mice, Fgf23 disruption in SEC was associated with marked changes in hematological parameters. Compared with older Tmprss6-/-Fgf23fl/fl mice, older Tmprss6-/-Fgf23SEC/SEC mice showed significantly higher hemoglobin (Hgb, 10.0 vs 8.4 g/dL), hematocrit (39.6 vs 30.7%), and RBC (13.60 vs 10.02 M/mL), as well as a trend towards lower spleen mass (0.0766 vs 0.2209 g, P=0.07). Preliminary biochemical analyses (n=3/group) showed that compared with older Tmprss6-/-Fgf23fl/fl mice, older Tmprss6-/-Fgf23SEC/SEC mice had lower plasma cFGF23 (447 vs 2211 pg/mL, P=0.10) and lower serum EPO (1329 vs 4107 pg/mL, P=0.17). Interestingly, Fgf23 disruption in SEC of older Tmprss6-/- mice was not accompanied by a rise in erythrocyte mean corpuscular volume, suggesting that the observed hematological benefits may not be attributable to increased iron delivery to erythroblasts. Additionally, the severity of iron-deficiency related thrombocytosis was also not attenuated by Fgf23 disruption in SEC of older Tmprss6-/- mice. Body mass was similar in older Tmprss6-/-Fgf23fl/fl and Tmprss6-/-Fgf23SEC/SEC mice, and comparison of systemic iron parameters is ongoing.
In summary, our findings suggest that in young male mice with or without IDA, SEC-derived FGF23 has minimal impact on plasma c-FGF23 levels and hematopoietic parameters. However, in older mice with anemia, SEC-derived FGF23 contributes to plasma c-FGF23 elevation and worsening of anemia. Notably, FGF23 has been described as a paracrine inhibitor of erythropoiesis,[PMID:24509850; PMID:42013007] and our findings suggest that this mechanism may have relevance to IDA in the setting of aging. Additionally, our results suggest that limiting the production or activity of SEC-derived FGF23 may represent a novel therapeutic strategy to improve anemia in older patients with IRIDA due to germline TMPRSS6 mutation.
DISCLOSURES
Karin Elisabeth Finberg, MD, PhD: No relevant conflicts of interest to declare.